N-(3-氯-4-氟苯基)-6-硝基-4-喹唑啉胺 | 184356-50-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: N-(3-氯-4-氟苯基)-6-硝基-4-喹唑啉胺
• 英文名称: N-(3-chloro-4-fluorophenyl)-6-nitroquinazolin-4-amine
• 英文别名: 4-(3'-chloro-4'-fluoroanilino)-6-nitroquinazoline
• CAS: 184356-50-1
• 化学式: C₁₄H₈ClFN₄O₂
• 分子量: 318.695
• InChiKey: OXLCCXLHESAETR-UHFFFAOYSA-N

物化性质

• 熔点：
  274.5-277 °C
• 沸点：
  477.0±45.0 °C(Predicted)
• 密度：
  1.561±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  83.6
• 氢给体数：
  1
• 氢受体数：
  6

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  N-(3-氯-4-氟苯基)-6-硝基-4-喹唑啉胺 在 铁粉 、 溶剂黄146 作用下， 以 乙醇 为溶剂， 反应 5.5h， 生成 2-{[4-(3-chloro-4-fluorophenylamino)quinazolin-6-ylimino]methyl}benzene-1,4-diol
  参考文献：
  名称：

  4-Anilinoquinazolines with Lavendustin A subunit as inhibitors of epidermal growth factor receptor tyrosine kinase: syntheses, chemical and pharmacological properties

  摘要：

  4-Anilinoquinazoline derivatives are widely investigated due to their potent epidermal growth factor receptor (EGFR) tyrosine kinase inhibitory activity. Two 4-anilinoquinazolines with Lavendustin A subunit (10a,b) were synthesized and examined for their EGFR tyrosine kinase inhibitory activity as well as their antiproliferative properties on variant human cancer cell lines. Both compounds maintained their EGFR tyrosine kinase inhibitory activity at the 10-7 M level and led to significant growth inhibition in certain leukemia, non-small cell lung cancer (NSCLC). ovarian cancer. renal cancer and breast cancer cell lines with GI(50) values at the 10-6 M level. There could not be observed any notable difference between 10a and lob regarding to their antiproliferative activity. Interestingly, we observed the high tendency of 10a and 10b to include certain solvents. e.g. water. DMF, DMSO, which may be due to the remarkable number of hydrogen accepting/donating groups in 10a and b. An X-ray analysis of 10a including water and DMF illustrates a possible hydrogen bond pattern and could serve as information for preferred receptor (e.g. EGFR tyrosine kinase) binding sites. Finally, we aimed for irreversible EGFR tyrosine kinase inhibitors. The p-quinone derivatives 11a and 11b, which contain a Michael acceptor position according to the irreversible inhibitor CI-1033. Could be derived from the p-hydroquinone derivatives 10a or 10b, respectively, by oxidation. However, due to their instability 11a and 11b could not be obtained in a pure form. (C) 2004 Elsevier SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2004.03.010
• 作为产物：
  描述：

  2-氰基-4-硝基苯胺 在 溶剂黄146 作用下， 生成 N-(3-氯-4-氟苯基)-6-硝基-4-喹唑啉胺
  参考文献：
  名称：

  EGFR/DNA双靶向策略治疗EGFRL858R/T790M突变肺癌的抗肿瘤活性及机制

  摘要：

  双靶点或多靶点 EGFR 抑制剂作为单一药物可以克服 EGFR 抑制剂耐药性并规避联合治疗的许多缺点。在这项工作中，设计并合成了 15 个带有氮芥或半芥部分的 4-苯胺基喹唑啉衍生物作为双 EGFR-DNA 靶向抗癌剂。目标分子的结构通过1 H NMR、13 C NMR 和 HR-MS确证，并使用 MTT 法评估其体外抗增殖活性。化合物6g成为针对突变型 H1975 细胞的最有效衍生物，IC 为50值为 1.45 μM，其效力比 Chl/Gef（苯丁酸氮芥和吉非替尼的等摩尔组合）强 4 倍。激酶抑制研究表明，6g对 EGFR L858R/T790M酶有极好的抑制作用，是吉非替尼的 8.6 倍。机理研究表明，6g以剂量依赖的方式诱导 H1975 细胞凋亡，并引起 DNA 损伤。重要的是，6g可显着抑制H1975细胞中p-EGFR及其下游p-AKT和p-ERK的表达。还进行了分子对接以深入了解EGFR

  DOI：

  10.1016/j.bioorg.2023.106510

文献信息

• A novel strategy to the synthesis of 4-anilinoquinazoline derivatives
  作者：Zheng Wang、Cuiling Wang、Yanni Sun、Ning Zhang、Zhulan Liu、Jianli Liu

  DOI：10.1016/j.tet.2013.12.028

  日期：2014.1

  A novel approach to prepare 4-anilinoquinazoline derivatives based on the transformation of indoline-2,3-dione to formamidine was developed. The processes with this approach are simple, efficient, and environmentally friendly. The efficiency of this approach was evaluated by synthesizing 17 4-anilinoquinazolines and comparing the obtained yields with those achievable through conventional synthetic

  开发了一种基于吲哚啉-2,3-二酮向甲am的转化制备4-苯胺基喹唑啉衍生物的新方法。使用这种方法的过程简单，高效且对环境友好。通过合成17种4-苯胺基喹唑啉并将获得的收率与通过常规合成方法可获得的收率进行比较，评估了该方法的效率。这是第一次合成化合物8d，8e，8h和13b - f。观察到这些化合物的IR和UV光谱的特征以及它们的取代基对光谱的影响。
• Quinazoline derivatives
  申请人：Zeneca Limited

  公开号：US05866572A1

  公开（公告）日：1999-02-02

  The invention concerns quinazoline derivatives of the formula I ##STR1## wherein X.sup.1 is a direct link or a group such as CO, C(R.sup.2).sub.2 and CH(OR.sup.2); wherein Q.sup.1 is phenyl, naphthyl or a 5- or 6-membered heteroaryl moiety and Q.sup.1 optionally bears up to 3 substituents; wherein m is 1 or 2 and each R.sup.1 may be a group such as hydrogen, halogeno and trifluoromethyl; and wherein Q.sup.2 may be phenyl or a 9- or 10-membered bicyclic heterocyclic moiety and Q.sup.2 optionally bears up to 3 substituents; or a pharmaceutically-acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them and the use of their receptor tyrosine kinase inhibitory properties in the treatment of proliferative disease such as cancer.

  该发明涉及式I的喹唑啉衍生物##STR1##其中X.sup.1是直链或类似CO、C(R.sup.2).sub.2和CH(OR.sup.2)的基团；其中Q.sup.1是苯基、萘基或5-或6-成员杂芳基，Q.sup.1可选地带有最多3个取代基；其中m为1或2，每个R.sup.1可以是氢、卤代或三氟甲基等基团；Q.sup.2可以是苯基或9-或10-成员的双环杂环基，Q.sup.2可选地带有最多3个取代基；或其药学上可接受的盐；它们的制备方法，含有它们的药物组合物以及利用它们的受体酪氨酸激酶抑制性能治疗增殖性疾病如癌症。
• Identification of 4-anilino-6-aminoquinazoline derivatives as potential MERS-CoV inhibitors
  作者：Jun Young Lee、Young Sup Shin、Jihye Lee、Sunoh Kwon、Young-hee Jin、Min Seong Jang、Seungtaek Kim、Jong Hwan Song、Hyoung Rae Kim、Chul Min Park

  DOI：10.1016/j.bmcl.2020.127472

  日期：2020.10

  New therapies for treating coronaviruses are urgently needed. A series of 4-anilino-6-aminoquinazoline derivatives were synthesized and evaluated to show high anti-MERS-CoV activities. N4-(3-Chloro-4-fluorophenyl)-N6-(3-methoxybenzyl)quinazoline-4,6-diamine (1) has been identified in a random screen as a hit compound for inhibiting MERS-CoV infection. Throughout optimization process, compound 20 was

  迫切需要治疗冠状病毒的新疗法。合成并评估了一系列 4-苯胺基-6-氨基喹唑啉衍生物，显示出高抗 MERS-CoV 活性。N 4 -(3-氯-4-氟苯基)- N 6 -(3-甲氧基苄基)喹唑啉-4,6-二胺 ( 1 ) 已在随机筛选中被鉴定为抑制 MERS-CoV 感染的热门化合物。在整个优化过程中，发现化合物20表现出高抑制作用（IC 50 = 0.157 μM，SI = 25），无细胞毒性，体内PK 特性适中。
• 4-아미노-퀴나졸린 유도체 및 이를 포함하는 항바이러스용 조성물
  申请人：KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY 한국화학연구원(319980077651)

  公开号：KR20210038042A

  公开（公告）日：2021-04-07

  본 발명은 4-아미노-퀴나졸린(4-amino-quinazoline) 유도체 또는 이의 약제학적으로 허용가능한 염과 이의 제조방법 및 이를 유효활성 성분으로 함유하는 바이러스 치료제에 관한 것이다.

  这项发明涉及4-氨基喹唑啉（4-amino-quinazoline）衍生物或其药学上可接受的盐以及其制备方法，以及包含其作为有效活性成分的抗病毒药物。
• Facile and efficient synthesis and biological evaluation of 4-anilinoquinazoline derivatives as EGFR inhibitors
  作者：Zheng Wang、Xue Wu、Li Wang、Jiao Zhang、Jianli Liu、Zhongxing Song、Zhishu Tang

  DOI：10.1016/j.bmcl.2016.04.032

  日期：2016.6

  Series of 4-anilinoquinazoline derivatives were conveniently and efficiently synthesized and their antitumor activities were evaluated by MTT assay in three human cancer cell lines: H1975, HepG2 and SMMC-7721. New compounds 19a-19h were designed and synthesized to seek for powerful EGFR inhibitors and to explore whether methyl group at C-2 position of quinazoline ring has a positive effect on EGFR

  方便，有效地合成了一系列4-苯胺基喹唑啉衍生物，并通过MTT分析在三种人类癌细胞系H1975，HepG2和SMMC-7721中评估了它们的抗肿瘤活性。设计并合成了新的化合物19a-19h，以寻找功能强大的EGFR抑制剂，并探索喹唑啉环C-2位处的甲基是否对EGFR抑制具有积极作用。发现19a-19h的所有化合物对所有三种细胞系均有效，并且发现5种化合物（19c，19d和19f-19h）对H1975的毒性高于吉非替尼。SAR研究表明，喹唑啉环C-2位的甲基可以显着提高4-苯胺基喹唑啉的抗肿瘤能力。根据蛋白质印迹分析的结果也得出了相同的结论。在所有测试的化合物中，19g对H1975表现出极强的效力，IC50值为0.11μM，明显低于吉非替尼（1.23μM）。Western印迹分析的结果表明，化合物19c和19g可以显着抑制磷酸化EGFR的表达，尤其是19g几乎完全被抑制。